TP53 and neoplasm: Detection of TP53 alterations in circulating tumor DNA prior to ARTA start in mCRPC patients was also correlated with the development of rapid resistance and adverse prognosis [58,73], and a retrospective analysis of circulating tumor cells (CTCs) in CRPC patients after progression on abiraterone/enzalutamide showed that CTCs harboring TP53 mutations were enriched in resistant patients [74].